Wall Street analysts expect that Opko Health Inc. (NASDAQ:OPK) will announce sales of $307.44 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Opko Health’s earnings. The lowest sales estimate is $296.51 million and the highest is $325.20 million. Opko Health reported sales of $275.50 million during the same quarter last year, which would suggest a positive year over year growth rate of 11.6%. The business is scheduled to report its next earnings report on Wednesday, March 7th.

On average, analysts expect that Opko Health will report full year sales of $307.44 million for the current fiscal year, with estimates ranging from $1.17 billion to $1.20 billion. For the next financial year, analysts forecast that the firm will report sales of $1.29 billion per share, with estimates ranging from $1.26 billion to $1.34 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Opko Health.

Opko Health (NASDAQ:OPK) last announced its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03). Opko Health had a negative net margin of 9.45% and a negative return on equity of 5.17%. The company had revenue of $263.50 million for the quarter, compared to analyst estimates of $319.43 million. During the same quarter last year, the company posted ($0.03) EPS. Opko Health’s revenue was down 11.6% on a year-over-year basis.

A number of research firms have recently issued reports on OPK. JPMorgan Chase & Co. lowered Opko Health from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $12.00 to $7.00 in a report on Thursday, September 14th. BidaskClub upgraded Opko Health from a “sell” rating to a “hold” rating in a report on Saturday, September 23rd. Ladenburg Thalmann Financial Services restated a “buy” rating and issued a $16.00 target price on shares of Opko Health in a report on Monday, September 25th. Zacks Investment Research lowered Opko Health from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. Finally, Cantor Fitzgerald set a $20.00 target price on Opko Health and gave the company a “buy” rating in a report on Thursday, October 12th. One analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the stock. Opko Health currently has a consensus rating of “Buy” and a consensus target price of $13.97.

Shares of Opko Health (OPK) opened at $4.92 on Wednesday. Opko Health has a 52-week low of $4.50 and a 52-week high of $12.03. The company has a market capitalization of $2,750.00, a price-to-earnings ratio of -25.89 and a beta of 1.81. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.48 and a current ratio of 1.66.

In other news, major shareholder Opko Health, Inc. acquired 655,738 shares of the business’s stock in a transaction that occurred on Monday, October 30th. The stock was acquired at an average cost of $3.05 per share, for a total transaction of $2,000,000.90. Following the completion of the acquisition, the insider now owns 6,678,752 shares in the company, valued at $20,370,193.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 40.19% of the stock is currently owned by company insiders.

A number of institutional investors have recently bought and sold shares of the business. Blair William & Co. IL acquired a new stake in shares of Opko Health in the second quarter valued at about $112,000. Crossmark Global Holdings Inc. acquired a new stake in shares of Opko Health in the third quarter valued at about $118,000. Engineers Gate Manager LP acquired a new stake in shares of Opko Health in the second quarter valued at about $117,000. Abbot Financial Management Inc. acquired a new stake in shares of Opko Health in the second quarter valued at about $129,000. Finally, BB&T Securities LLC grew its position in shares of Opko Health by 7.6% in the second quarter. BB&T Securities LLC now owns 20,600 shares of the biotechnology company’s stock valued at $135,000 after purchasing an additional 1,460 shares during the last quarter. 22.90% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This report was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/12/27/analysts-expect-opko-health-inc-opk-will-post-quarterly-sales-of-307-44-million.html.

Opko Health Company Profile

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Get a free copy of the Zacks research report on Opko Health (OPK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.